Влияние компонентов системы интерлейкина-6 на развитие атеросклероза коронарных артерий

A. I. Kaminnyi; S. A. Moskalenko; Yu. A. Shuvalova

doi:10.34687/2219-8202.JAD.2022.02.0005

Authors

A. I. Kaminnyi
S. A. Moskalenko
Yu. A. Shuvalova

DOI:

https://doi.org/10.34687/2219-8202.JAD.2022.02.0005

Keywords:

Interleukin-6; soluble IL-6 receptor; soluble gp130 transducer protein; coronary atherosclerosis.

Abstract

Objective: To carry out a comprehensive assessment of the interaction between components of the inyerleukin-6 (IL-6) system and atherosclerotic coronary artery (CA) lesions.

Material and Methods: Patients with documented coronary artery disease (n=387) and intact coronary arteries (n=92) were included in the study. Plasma levels of IL-6, soluble IL-6 receptor, and soluble glycoprotein 130 (sgp130) were determined by ELISA using the R&D Systems VR Minneapolis, MN kit.

Results: IL-6 levels were significantly higher in patients with affected CA than in controls (3.58 vs 2.04 pg/mL; p < 0.009), whereas sgp130 levels were significantly lower (317 vs 361 ng/mL; p < 0.006); the groups did not differ in soluble IL-6 receptor levels (56.4 vs 55.8 ng/mL; p < 0.088). A single-factor regression analysis revealed an association of atherosclerotic CA lesions with both IL-6 levels (OR=3.5; 95% CI: 1.6-8.0) and sgp130 levels (OR=0.34; 95% CI: 0.16-0.72). No association of coronary atherosclerosis with IL-6 levels was detected in a multivariate analysis corrected for traditional risk factors (OR=3.3; 95% CI: 0.87-12.3), while the association with sgp-130 levels persisted (OR=0.22; 95% CI: 0.06-0.8). To understand the interaction between the levels of IL-6 and sgp130 with atherosclerotic CA lesions, a pairwise and partial correlation analysis was performed. Paired correlation analysis revealed a direct correlation of coronary atherosclerosis with IL-6 levels (r = 0.17; p = 0.023) and an inverse correlation with sgp 130 levels (r = - 0.22; p = 0.006). When analyzing private correlations, the correlation between coronary atherosclerosis and IL-6 level controlled by sgp 130 level becomes insignificant, while the private correlation between coronary atherosclerosis and sgp 130 level controlled by IL-6 level maintains statistical validity (r = 0.22; p = 0.04).

Conclusions: The results suggest that the development of atherosclerotic lesion of the coronary artery is influenced not so much by the increased level of IL-6 in the body as by the decreased level of sgp130.

Downloads

Download data is not yet available.

References

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi: 10.1056/NEJMoa1707914

Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-328. doi: 10.1016/S0140-6736(17)32814-3.

Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-2505. doi: 10.1056/NEJMoa1912388.

Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996;127(2):263-271. doi: 10.1016/s0021-9150(96)05968-0.

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878-888. doi: 10.1016/j.bbamcr.2011.01.034.

Rose-John S. The soluble Interleukin 6 receptor: Advanced therapeutic options in inflammation. Clin Pharmacol Ther. 2017;102(4):591-598. doi: 10.1002/cpt.782.

Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015;26(5):475-487. doi: 10.1016/j.cytogfr.2015.07.004.

Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membraneanchored gp130. Blood. 1993;82(4):1120-1126. https://doi.org/10.1182/blood.V82.4.1120.1120

Kaptoge S, Seshasai SRK, Gao P, Freitag DF, Butterworth AS, Borglykke A et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578-89. doi: 10.1093/eurheartj/eht367.

Rifai N, Joubran R, Yu H, Asmi M, Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clinical Chemistry. 1999;45(11):1967-1973. https://doi.org/10.1093/clinchem/45.11.1967.

Eltoft A, Arntzen KA, Wilsgaard T, Mathiesen EB, Johnsen SH. Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: The Tromsø Study. Atherosclerosis.l 2018: 271:1-8. doi: 10.1016/j.atherosclerosis.2018.02.005.

Lee KWJ, Hill JS, Walley KR, Frohlich JJ. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort CMAJ. 2006;174(4):461-466. doi: 10.1503/cmaj.050880.

Walter J, Tanglay Y, du Fay de Lavallaz J, Strebel I, Boeddinghaus J, Twerenbold R et al. Clinical utility of circulating interleukin-6 concentrations in the detection of functionally relevant coronary artery disease. Int J Cardiol. 2019 Jan 15;275:20-25. doi: 10.1016/j.ijcard.2018.10.029.

Fraser A, May M, Lowe G, Rumley A, Smith GD, Ebrahim S, Lawlor DA. Interleukin-6 and incident coronary heart disease: results from the British Women's Heart and Health Study. Atherosclerosis. 2009;202(2):567-72. doi: 10.1016/j.atherosclerosis.2008.04.048.

Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa . C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost. 2006;95(3):511-518. doi: 10.1160/TH05-08-0571.

Ritschel VN, Seljeflot I, Arnesen H, Halvorsen S, Eritsland J, Fagerland MW, Andersen GØ. Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction. J Am Heart Assoc. 2016;5(6):e003014. doi: 10.1161/JAHA.115.003014

Velásquez IM, Golabkesh Z, Källberg H, Leander K, de Faire U, Gigante B. Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction. Atherosclerosis. 2015;240(2):477-81. doi: 10.1016/j.atherosclerosis.2015.04.014.

Korotaeva AA, Samoilova EV, Chepurnova DA, Zhitareva IV, Shuvalova YA, Prokazova NV. Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis. Biomarkers. 2018;23(6):527-532. doi: 10.1080/1354750X.2018.1458151.